Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- 5 November 2009
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 21 (1), 84-92
- https://doi.org/10.1021/bc900315y
Abstract
Antibody−drug conjugates (ADCs) are designed to eradicate cancer cells that express the target antigen on their cell surface. A key component of an ADC is the linker that covalently connects the cytotoxic agent to the antibody. Several antibody−maytansinoid conjugates prepared with disulfide-based linkers such as those targeting the CanAg antigen have been shown to display more activity in preclinical mouse xenograft models than corresponding conjugates prepared with uncleavable thioether-based linkers. To investigate how the linker influences delivery and activation of antibody−maytansinoid conjugates, we isolated and characterized the [3H]maytansinoids from CanAg-positive tumor tissues following a single intravenous administration of 300 μg/kg (based on maytansinoid dose) of anti-CanAg antibody (huC242)-3H-maytansinoid conjugates prepared with cleavable disulfide linkers and an uncleavable thioether linker. We identified three target-dependent tumor metabolites of the disulfide-linked huC242-SPDB-DM4, namely, lysine-Nε-SPDB-DM4, DM4, and S-methyl-DM4. We found similar metabolites for the less hindered disulfide-linked huC242-SPP-DM1 conjugate with the exception that no S-methyl-DM1 was detected. The sole metabolite of the uncleavable thioether-linked huC242-SMCC-DM1 was lysine-Nε-SMCC-DM1. The AUC for the metabolites of huC242-SMCC-DM1 at the tumor over 7 d was about 2-fold greater than the corresponding AUC for the metabolites of the disulfide-linked conjugates. The lipophilic metabolites of the disulfide-linked conjugates were found to be nearly 1000 times more cytotoxic than the more hydrophilic lysine-Nε-linker-maytansinoids in cell-based viability assays when added extracellularly. The cell killing properties associated with the lipophilic metabolites of the disulfide-linked conjugates (DM4 and S-methyl-DM4, and DM1) provide an explanation for the superior in vivo efficacy that is often observed with antibody−maytansinoid conjugates prepared with disulfide-based linkers in xenograft mouse models.Keywords
This publication has 21 references indexed in Scilit:
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug ConjugateCancer Research, 2008
- Novel Peptide Linkers for Highly Potent Antibody−Auristatin ConjugateBioconjugate Chemistry, 2008
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic DrugsAccounts of Chemical Research, 2007
- Semisynthetic Maytansine Analogues for the Targeted Treatment of CancerJournal of Medicinal Chemistry, 2006
- Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular ProcessingCancer Research, 2006
- Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicityBioconjugate Chemistry, 2005
- Drug-conjugated monoclonal antibodies for the treatment of cancerCurrent Opinion in Pharmacology, 2005
- Arming antibodies: prospects and challenges for immunoconjugatesNature Biotechnology, 2005
- Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in MiceThe Journal of pharmacology and experimental therapeutics, 2003
- An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of LinkerBioconjugate Chemistry, 2001